Diagnexia
Global network of expert pathologists connected through digital platform for rapid diagnostics
Platform · Cloud SaaSCompany source
Company profile
About Deciphex
Deciphex is transforming pathology through AI-powered digital platforms and a global network of expert pathologists. The company addresses critical shortages in pathology resources by enabling remote, accurate diagnostics at scale. Deciphex operates through three integrated brands: Patholytix, an AI-powered digital platform streamlining regulated research workflows for drug safety; Diagnexia, a global network of subspecialty pathologists connected through a digital platform providing 24/7 diagnostic services; and an integrated platform accelerating end-to-end drug development. The company serves 9 out of 10 top pharmaceutical companies, helping accelerate preclinical drug development while reducing pathologist review time by over 20%. In the NHS, Deciphex has reduced pathology wait times from 2 months to 2 days through AI-powered platforms that integrate directly with NHS systems. The company maintains the world's largest repository of digital slides and is pioneering pathologist-centric foundation models. Deciphex collaborates with leading organizations including Novartis, Charles River Laboratories, and NHS Trusts to advance AI in pathology. The company is committed to democratizing access to high-quality pathology, including pro-bono support in underserved areas, while ensuring every patient worldwide receives accurate diagnoses and effective treatments promptly.
Company description Deciphex official website
Primary marketPathology & Laboratory Diagnostics
Commercial modelCommercial information available on request
Work at Deciphex?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Dose range finding studies
- Drug safety assessments
- Histopathology
- Lead optimization studies
- Preclinical toxicology
Who it serves
- Clinical laboratories
- Health Systems
- NHS Trusts
- Pharmaceutical companies
- Research organizations
Deployment & integration
Cloud Saas · Embedded deployment with recorded integration context.
Recorded integration context: NHS systems.
Geographic context
MarketsCanada · Global · Ireland · Switzerland · United Kingdom · United States
Company sourceOfficial website
Company milestones
Platform expansion
Secured €15M venture debt facility from Claret Capital Partners (October 2025). Achieved full UKAS accreditation for Oxford Histopathology Laboratory and Digital Pathology Services (November 2025). Developed Foresight suite of pre-trained AI models with Charles River Laboratories.
Partnerships
Recorded partners
- Charles River Laboratories
- Claret Capital Partners
- IHI JU VICT3R project
- NHS Trusts
- Novartis
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Digital Pathology Platform
Integrated platform accelerating end-to-end drug development through objective analysis
Platform · Cloud SaaSCompany source
Foresight
Pre-trained AI models for faster drug candidate qualification in preclinical development
Model · EmbeddedCompany source
Patholytix
AI-powered digital platform streamlining regulated research workflows for enhanced drug safety
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Despite simplified diagnostic criteria, intraobserver and interobserver variability remain in the interpretation of colorectal serrated polyps.Histopathology · Jun 1, 2026
Artificial intelligence and computational pathology: reality and perceptions.Journal of clinical pathology · May 18, 2026
Keratin 7 immunohistochemistry reveals patterns of cell populations in liver biopsies from patients with MASLD.Journal of clinical pathology · May 18, 2026
Are deeper sections and immunohistochemistry useful in detecting micrometastases and isolated tumour cells in colorectal cancer?Pathology · Oct 1, 2025
Use of quality checks and processes across digital histopathology: an initial survey from the Bigpicture consortium.Journal of clinical pathology · Sep 18, 2025
Digital Pathology and Artificial Intelligence Applied to Nonclinical Toxicology Pathology-The Current State, Challenges, and Future Directions.Toxicologic pathology · Aug 1, 2025
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Pathologist review time reduction
Over 20% reduction in preclinical studies
Diagnostic wait time reduction
From 2 months to 2 days for NHS pathology
Drug development acceleration
Serving 9/10 top pharma companies
Animal testing reduction
Through virtual controls and AI-based screening
9 out of 10 top pharma companies
Speeding up drug development with GLP-compliant digital pathology for preclinical studies
Accelerated pathology reporting and testing of hundreds of drug compounds
Charles River Laboratories
AI-based lesion screening for Lead Optimization and Dose Range Finding studies
Reduced pathologist review time by over 20%
NHS Trusts
Reducing pathology diagnostic wait times and achieving 28-day Faster Diagnosis Standard
Reduced wait times from 2 months to 2 days
Novartis
Developing next-generation foundational AI models for lesion detection across species
Enhanced efficiency and reliability of toxicologic assessments in preclinical safety
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Donal O'Shea
Chief Executive Officer
Mairin Rafferty
Chief of Staff
Greg Wigmore
Chief Financial Officer
Jenny Fitzgerald
Chief Revenue Officer
Runjan Chetty
Chief Medical Officer
Pierre Moulin
Chief Scientific Officer
Andrea Rizzini
Chief Technology Officer
Mirko Colleluori
Chief Information Officer
06 · Company updates
Updates from Deciphex
Recent articles published on Deciphex's official website.
Diagnexia Achieves Full UKAS Accreditation for Oxford Histopathology Laboratory and Digital Pathology Services
Read on DeciphexDiagnexia Achieves Full UKAS Accreditation for Oxford Histopathology Laboratory and Digital Pathology Services
Read on DeciphexAI Has Arrived in Pathology, And It’s Seeing What We Couldn’t
Read on DeciphexRewriting the Rules of Pathology: Diagnexia's Shift from Service Provider to Vital Partner
Read on Deciphex07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Pathology & Laboratory Diagnostics
Companies applying AI to digital pathology, histopathology slide analysis, laboratory diagnostics, or biomarker discovery. Includes AI-powered interpretation of lab test results, at-home diagnostic devices with AI analysis, and platforms that analyze tissue samples or biological specimens to support clinical diagnosis.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.